{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Copanlisib+%28Aliqopa%2C+BAY80-6946%29", "query": { "intervention": "Copanlisib (Aliqopa, BAY80-6946)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Copanlisib+%28Aliqopa%2C+BAY80-6946%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T05:01:15.882Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03517956", "title": "Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "Rogaratinib (BAY1163877)", "type": "DRUG" }, { "name": "Copanlisib (BAY80-6946)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-07-25", "completion_date": "2021-02-01", "has_results": false, "last_update_posted_date": "2022-07-14", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 7, "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517956" }, { "nct_id": "NCT01460537", "title": "Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "BAY80-6946", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "NaCl", "type": "DRUG" }, { "name": "BAY80-6964 fixed dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2011-11-18", "completion_date": "2015-12-18", "has_results": false, "last_update_posted_date": "2017-10-04", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 3, "location_summary": "Tampa, Florida • Rochester, Minnesota • Chapel Hill, North Carolina", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460537" }, { "nct_id": "NCT03655301", "title": "Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Copanlisib (Aliqopa, BAY80-6946)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 13, "start_date": "2018-09-11", "completion_date": "2019-02-12", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03655301" }, { "nct_id": "NCT02367040", "title": "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma,Non-Hodgkin" ], "interventions": [ { "name": "Copanlisib (Aliqopa, BAY80-6946)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 458, "start_date": "2015-08-03", "completion_date": "2024-11-15", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 16, "location_summary": "West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more", "locations": [ { "city": "West Covina", "state": "California" }, { "city": "Ashland", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367040" }, { "nct_id": "NCT03458728", "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Solid Tumors or Lymphoma in Children", "Neuroblastoma", "Osteosarcoma", "Rhabdomyosarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Copanlisib (BAY806946)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 31, "start_date": "2018-04-30", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2023-12-04", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Orange, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03458728" }, { "nct_id": "NCT02455297", "title": "Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "Copanlisib (BAY80-6946)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-08-24", "completion_date": "2016-08-31", "has_results": false, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Hackensack, New Jersey • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455297" }, { "nct_id": "NCT06360588", "title": "Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 22, "start_date": "2018-10-08", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06360588" }, { "nct_id": "NCT03502733", "title": "Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-08-14", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03502733" }, { "nct_id": "NCT02626455", "title": "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Copanlisib (BAY80-6946)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 551, "start_date": "2016-01-06", "completion_date": "2023-11-10", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 10, "location_summary": "Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "West Covina", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Thomasville", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02626455" }, { "nct_id": "NCT01660451", "title": "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Copanlisib (Aliqopa, BAY80-6946)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2012-11-19", "completion_date": "2023-05-18", "has_results": true, "last_update_posted_date": "2024-07-17", "last_synced_at": "2026-10-04T05:01:15.882Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660451" } ] }